title: Severe Sepsis and Septic Shock Trials (ProCESS, ARISE, ProMISe): What is Optimal Resuscitation?
abstract: Between 2014 and 2015, 3 independent, multicenter, randomized controlled trials evaluated early goal-directed therapy (EGDT) in severe sepsis and septic shock: Protocolized Care for Early Septic Shock (ProCESS) from the United States; Australasian Resuscitation in Sepsis Evaluation (ARISE), and Protocolised Management in Sepsis (ProMISe) in the United Kingdom. All 3 trials confirmed that there was no survival benefit of EGDT compared to usual resuscitation. How should we define usual care for sepsis given these study findings? Furthermore, the definition of sepsis has now been updated. This article reviews key findings of these 3 trials and discusses these important issues in sepsis management.
authors.affiliation: Section of Acute and Critical Care Surgery, Washington University School of Medicine, 4901 Forest Park Avenue, St. Louis, MO 63108, USA. Electronic address: osbornt@wustl.edu.
authors.forename: Tiffany M
authors.initials: TM
authors.lastname: Osborn
mesh_terms: D006801:Humans; D010347:Patient Care Planning; D016032:Randomized Controlled Trials as Topic; D012151:Resuscitation / Q000379:methods*; D018805:Sepsis / Q000401:mortality / Q000628:therapy*; D012772:Shock, Septic / Q000401:mortality / Q000628:therapy*
keywords: Hyperlactatemia; Lactate; Resuscitation; Sepsis; Septic shock; Severe sepsis; Usual care